Ocular Therapeutix (OCUL) Free Cash Flow (2013 - 2026)
Ocular Therapeutix's quarterly Free Cash Flow came in at -$67.3 million in Q1 2026, down 44.45% year-on-year from -$121.2 million in Q1 2025, and down 45.55% quarter-over-quarter from -$46.3 million in Q4 2025.
Ocular Therapeutix has reported Free Cash Flow for 14 years, with the latest figure at -$67.3 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 44.45% year-over-year to -$67.3 million; the trailing twelve-month figure through Mar 2026 stood at -$226.8 million (down 53.99% YoY), and the FY2025 full-year result was -$206.1 million, down 52.86% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$67.3 million, down from -$46.3 million in the prior quarter.
- The five-year high for Free Cash Flow was -$8.0 million in Q3 2023, with the low at -$67.3 million in Q1 2026.
- Average Free Cash Flow over 5 years is -$31.9 million, with a median of -$25.5 million recorded in 2024.
- Year-over-year, Free Cash Flow jumped 45.92% in 2022 and sank 345.98% in 2024.
- Tracing OCUL's Free Cash Flow over 5 years: stood at -$20.2 million in 2022, then rose by 16.61% to -$16.8 million in 2023, then sank by 134.38% to -$39.5 million in 2024, then retreated by 17.17% to -$46.3 million in 2025, then slumped by 45.55% to -$67.3 million in 2026.
- The last three Free Cash Flow figures came in at -$67.3 million (Q1 2026), -$46.3 million (Q4 2025), and -$56.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | -67.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -67.32 Mn |
| Mar 31, 2026 | -67.32 Mn |
| Dec 31, 2025 | -46.25 Mn |
| Dec 31, 2025 | -46.25 Mn |
| Sep 30, 2025 | -56.72 Mn |
| Sep 30, 2025 | -56.72 Mn |
| Jun 30, 2025 | -56.48 Mn |
| Jun 30, 2025 | -56.48 Mn |
| Mar 31, 2025 | -46.60 Mn |
| Mar 31, 2025 | -46.60 Mn |
| Dec 31, 2024 | -39.47 Mn |
| Dec 31, 2024 | -39.47 Mn |
| Sep 30, 2024 | -35.64 Mn |
| Sep 30, 2024 | -35.64 Mn |
| Jun 30, 2024 | -25.54 Mn |
| Jun 30, 2024 | -25.54 Mn |
| Mar 31, 2024 | -34.14 Mn |
| Mar 31, 2024 | -34.14 Mn |
| Dec 31, 2023 | -16.84 Mn |
| Dec 31, 2023 | -16.84 Mn |
| Sep 30, 2023 | -7.99 Mn |
| Sep 30, 2023 | -7.99 Mn |
| Jun 30, 2023 | -24.80 Mn |
| Jun 30, 2023 | -24.80 Mn |
| Mar 31, 2023 | -20.62 Mn |
| Mar 31, 2023 | -20.62 Mn |
| Dec 31, 2022 | -20.20 Mn |
| Dec 31, 2022 | -20.20 Mn |
| Sep 30, 2022 | -13.40 Mn |
| Sep 30, 2022 | -13.40 Mn |
| Jun 30, 2022 | -10.85 Mn |
| Jun 30, 2022 | -10.85 Mn |
| Mar 31, 2022 | -18.88 Mn |
| Mar 31, 2022 | -18.88 Mn |
| Dec 31, 2021 | -15.78 Mn |
| Dec 31, 2021 | -15.78 Mn |
| Sep 30, 2021 | -13.54 Mn |
| Sep 30, 2021 | -13.54 Mn |
| Jun 30, 2021 | -20.05 Mn |
| Jun 30, 2021 | -20.05 Mn |
| Mar 31, 2021 | -17.37 Mn |
| Mar 31, 2021 | -17.37 Mn |
| Dec 31, 2020 | -6.27 Mn |
| Dec 31, 2020 | -6.27 Mn |
| Sep 30, 2020 | -13.36 Mn |
| Sep 30, 2020 | -13.36 Mn |
| Jun 30, 2020 | -14.92 Mn |
| Jun 30, 2020 | -14.92 Mn |
| Mar 31, 2020 | -19.10 Mn |
| Mar 31, 2020 | -19.10 Mn |
| Dec 31, 2019 | -19.22 Mn |
| Dec 31, 2019 | -19.22 Mn |
| Sep 30, 2019 | -18.79 Mn |
| Sep 30, 2019 | -18.79 Mn |
| Jun 30, 2019 | -20.22 Mn |
| Jun 30, 2019 | -20.22 Mn |
| Mar 31, 2019 | -19.56 Mn |
| Mar 31, 2019 | -19.56 Mn |
| Dec 31, 2018 | -12.39 Mn |
| Dec 31, 2018 | -12.39 Mn |
| Sep 30, 2018 | -12.19 Mn |
| Sep 30, 2018 | -12.19 Mn |
| Jun 30, 2018 | -11.94 Mn |
| Jun 30, 2018 | -11.94 Mn |
| Mar 31, 2018 | -12.85 Mn |
| Mar 31, 2018 | -12.85 Mn |
| Dec 31, 2017 | -10.61 Mn |
| Dec 31, 2017 | -10.61 Mn |
| Sep 30, 2017 | -13.43 Mn |
| Sep 30, 2017 | -13.43 Mn |
| Jun 30, 2017 | -10.75 Mn |
| Jun 30, 2017 | -10.75 Mn |
| Mar 31, 2017 | -16.23 Mn |
| Mar 31, 2017 | -16.23 Mn |
| Dec 31, 2016 | -8.29 Mn |
| Dec 31, 2016 | -8.29 Mn |
| Sep 30, 2016 | -8.38 Mn |
| Sep 30, 2016 | -8.38 Mn |
| Jun 30, 2016 | -9.88 Mn |
| Jun 30, 2016 | -9.88 Mn |
| Mar 31, 2016 | -9.37 Mn |
| Mar 31, 2016 | -9.37 Mn |
| Dec 31, 2015 | -9.11 Mn |
| Dec 31, 2015 | -9.11 Mn |
| Sep 30, 2015 | -9.78 Mn |
| Sep 30, 2015 | -9.78 Mn |
| Jun 30, 2015 | -9.40 Mn |
| Jun 30, 2015 | -9.40 Mn |
| Mar 31, 2015 | -7.23 Mn |
| Mar 31, 2015 | -7.23 Mn |
| Dec 31, 2014 | -5.76 Mn |
| Dec 31, 2014 | -5.76 Mn |
| Sep 30, 2014 | -6.29 Mn |
| Sep 30, 2014 | -6.29 Mn |
| Jun 30, 2014 | -4.30 Mn |
| Jun 30, 2014 | -4.30 Mn |
| Mar 31, 2014 | -4.32 Mn |
| Mar 31, 2014 | -4.32 Mn |
| Dec 31, 2013 | -3.41 Mn |
| Dec 31, 2013 | -3.41 Mn |
| Sep 30, 2013 | -2.98 Mn |
| Sep 30, 2013 | -2.98 Mn |